Our platform acts as a digital support system for multidisciplinary tumor boards, integrating seamlessly into the workflow of comprehensive cancer centers and clinical practices. Medicai enables the streamlined review and discussion of complex cancer cases, enhancing collaborative decision-making among specialists in oncology, radiology, pathology, and surgery.
Enhanced Data Integration: Medicai’s Cloud PACS stores patients' medical data, like medical imaging, histopathological data, genomic data, blood panels, and other clinical information, providing a comprehensive view that supports sophisticated analysis and discussion.
Real-Time Access and Collaboration: Facilitates synchronous and asynchronous collaboration among tumor board members, allowing for real-time communication and consultation during multidisciplinary or molecular tumor board meetings. Through Medicai, tumor boards are successfully organized online, offline, or in a hybrid mode.
Secure and Efficient Data Management: Ensures secure and efficient handling and sharing of sensitive patient data across various locations, maintaining compliance with healthcare regulations.
Integrated DICOM viewer: With our web and mobile DICOM viewer, you can view and analyze imaging studies, as well as perform accurate diagnosis in real time.
Improved Efficiency: Medicai provides integrated document signing (with DocuSign) and integrated audio-video calling (with Zoom).
Improved Patient Outcomes: Fosters a collaborative approach to treatment planning by ensuring that an interdisciplinary team thoroughly reviews each patient's case, resulting in more personalized and effective treatment strategies.
Enhanced Decision-Making: Provides clinicians with the tools to access and analyze detailed patient data, facilitating informed decisions about therapies, cancer diagnosis, and eligibility for clinical trials.
Medicai’s platform provides an intuitive interface for clinicians to manage and review a patient's medical file. By consolidating all relevant data in one place, Medicai supports effective and efficient multidisciplinary discussions, enabling specialists to make well-informed decisions based on comprehensive data.
Our multi-enterprise solution enables modern specialized healthcare providers to automatically retrieve imaging from their own PACS and modalities, allowing their patients to easily upload their previous imaging studies and other medical files.
Medicai's interoperable imaging infrastructure scales reliably with your practice needs. All the studies, together with complementary files (reports, images, and videos), are stored in a secure and compliant way (HIPAA, GDPR).
Because medical data is accessible from one place, advanced workflows like online multidisciplinary diagnostic boards become possible.
With integration with EHRs or EMRs, the doctors have a full picture of the patient's medical history.
You can organize MTBs online with Medicai. Besides fast and secure access to medical data (through our Doctor Portals and Doctor Mobile apps equipped with DICOM Viewers), doctors can coordinate and communicate, create reports, and sign them.
They can also share the case with other doctors from different organizations for expert opinions.
Give it a try, play with it! Using our embeddable DICOM Viewer, you can easily view your DICOM files anywhere online (web, in the mobile application). Your DICOM files are stored in your Medicai workspace, in your cloud PACS.
"We had international Tumor Boards meetings via Medicai with experts from Romania, Moldova, the US and Canada , reviewing images, discussing and planning best care. The platform has been a user-friendly, reliable and efficient tool enabling the international oncology team to care for these tragically displaced patients fighting for their cancer, fighting for their country."
Irena Tocino, MD, FACR
Professor, Thoracic Imaging, Informatics Department of Radiology and Biomedical Imaging @ Yale School of Medicine
Choosing Medicai’s Cloud PACS for tumor boards means opting for a platform that enhances efficiency and collaboration in cancer care. Our solution ensures that medical teams have the technology to facilitate detailed discussions and develop targeted treatment plans, ultimately improving the quality of patient care.
What is the significance of the role of MTBs in oncology tumor boards?
The role of molecular tumor boards (MTBs) within broader oncology tumor boards is to bring focused expertise on molecular diagnostics and precision medicine. They play a pivotal role in making informed decisions about personalized treatment plans, thus driving the evolution of cancer care towards more targeted and effective therapies.
How do molecular tumor boards serve as a clinical decision support system?
Molecular tumor boards function as a clinical decision support system by providing a multidisciplinary platform where experts review and discuss complex cancer cases. This collaborative approach allows for a comprehensive evaluation of available treatment options, supported by the latest genomic research and clinical data, ensuring informed decisions that are aligned with the best outcomes for patients.
What is the next generation of molecular tumor boards expected to focus on?
The next generation of molecular tumor boards is expected to integrate more advanced technologies, such as artificial intelligence and machine learning, to further enhance the precision of cancer treatment. These advancements will facilitate even more accurate genomic profiling and help refine clinical decision-making processes in real-time.
What learning programs are available for clinicians involved in molecular tumor boards?
Many institutions that host molecular tumor boards offer specialized learning programs designed to educate clinicians on the latest advancements in genomic medicine and cancer treatment. These programs often include training in clinical decision making, the use of clinical decision support systems, and best practices for interpreting genomic data.
How do molecular tumor boards contribute to reporting for precision oncology?
In precision oncology, molecular tumor boards enhance reporting by synthesizing complex genomic and clinical data into actionable insights. This reporting supports oncologists by providing clear guidance on therapy choices based on the genetic profile of the patient's tumor, thereby making precision oncology more accessible and effective.
What is the role of molecular tumor boards in precision therapy for solid tumors?
Molecular tumor boards are essential in precision therapy, especially for solid tumors, as they utilize detailed genomic data to tailor treatment approaches specific to the genetic makeup of each tumor. These boards assess molecular abnormalities to recommend precision therapies that target the unique aspects of each cancer, enhancing the efficacy of treatments.
What role do molecular tumor boards play in the clinical interpretation of cancer variants?
Molecular tumor boards provide a crucial service in the clinical interpretation of cancer variants by combining expertise from various oncology disciplines.
This collective expertise helps clarify the clinical relevance of mutational burdens and other genomic findings, supporting the precision oncology paradigm by aligning patient-specific data with the most effective therapy options.
How does the molecular tumor board schedule influence patient care at comprehensive cancer centers like Markey Cancer Center or UW Carbone Cancer Center?
The scheduling of MTB meetings, such as those at Markey Cancer Center or UW Carbone Cancer Center, is designed to ensure timely review of patient cases, allowing for rapid clinical decisions that can significantly impact treatment outcomes.
Regularly scheduled meetings ensure that all relevant clinical data, including recent findings from collaborative genomics cores, are discussed promptly to refine treatment plans continuously.
What advancements have molecular tumor boards brought to clinical oncology?
Molecular tumor boards have revolutionized clinical oncology by facilitating a forum for expert clinicians to discuss and decide on the best course of action for cancer patients.
This collaborative approach leverages next-generation sequencing and artificial intelligence to analyze complex cases, ensuring that each decision is informed by the latest research and best practices in genomic medicine.
How can clinicians access MTB meetings and related documents?
Clinicians can access MTB meetings and download guidance and MTB documents through a secure portal, often provided by the institution hosting the molecular tumor board.
This portal may also support real-time discussions, allowing for ongoing collaboration regardless of clinicians' current locations.
What are the benefits of genomic profiling in molecular tumor boards?
Genomic profiling in molecular tumor boards offers detailed insights into the genetic underpinnings of solid tumors and other cancers.
This information aids clinicians in identifying actionable mutations that can be targeted with specific treatments, thus enhancing the precision of cancer therapeutics and the overall clinical decision-making process.
How do molecular tumor boards influence clinical outcomes in metastatic breast cancer?
In cases of metastatic breast cancer, molecular tumor boards significantly enhance clinical outcomes by enabling targeted therapy based on precise genomic data.
By understanding the specific biomarkers and molecular alterations present in the tumor, these boards facilitate the use of precision cancer medicine, improving the efficacy of treatment protocols.
What is the role of molecular tumor boards in implementing precision oncology?
Molecular tumor boards (MTBs) play a critical role in the implementation of precision oncology by reviewing and interpreting complex cancer cases through genomic profiling and molecular screening studies.
These boards make treatment recommendations based on a patient’s molecular tumor profiles, driving personalized treatment plans that target specific genomic alterations and tumor genotypes.
What advancements have been made in treating cancer patients with unique molecular profiles?
Advancements in treating cancer patients with unique molecular profiles include the development of targeted therapies that specifically attack cancer cells based on their genetic abnormalities, minimizing damage to normal cells.
This precision oncology approach allows for more effective and less toxic treatment options, significantly improving the quality of life and survival rates for cancer patients.
Why is it essential to discuss cancer cases in molecular tumor boards for precision oncology?
Discussing cancer cases in molecular tumor boards is essential because it ensures a multidisciplinary approach to each case, combining insights from various experts to consider all possible aspects of cancer diagnosis, treatment, and patient care.
This collaborative effort often leads to more accurate diagnosis, optimized treatment plans, and better alignment of therapies with the patient’s specific medical and genetic context.
What is the significance of molecular test results in cancer development?
Molecular test results are significant in understanding cancer development as they reveal the genetic alterations that contribute to the growth and spread of cancer cells.
These results help clinicians predict how the cancer is likely to progress and respond to various treatments, aiding in the planning of a more strategic and targeted approach to care.
How does a molecular tumor board use genomic panels to improve cancer treatment?
Molecular tumor boards use genomic panels to assess the full spectrum of actionable mutations in a patient’s cancer. By reviewing comprehensive genomic data during an MTB meeting, the team of oncologists, molecular pathologists, and other specialists can decide on the most effective precision medicine approaches, including targeted therapies and enrollment in clinical trials relevant to the patient’s specific cancer type.
What information does a genomic report provide in a molecular tumor board meeting?
A genomic report in a molecular tumor board meeting provides detailed information about the genetic makeup of a patient’s tumor.
This report includes data on specific genomic abnormalities, the presence of targetable genes, and potential resistance to conventional therapies, which is crucial for developing a personalized cancer treatment plan.
How do molecular pathologists contribute to cancer diagnosis and treatment?
Molecular pathologists play a vital role in cancer diagnosis and treatment by analyzing genomic test results from cancer panels.
Their expertise helps determine the clinical relevance of specific genetic changes found in tumors, guiding oncologists in selecting the most appropriate therapies for advanced cancer types based on the molecular pathology of the disease.
What role does genomic testing play in modern cancer therapeutics?
Genomic testing is crucial in cancer therapeutics as it allows clinicians to identify specific genes and molecular abnormalities that drive the growth of cancer.
By understanding these genetic markers, doctors can tailor treatments to the unique genetic profile of each cancer patient, enhancing the effectiveness of therapy and often improving patient outcomes.
What is a virtual tumor board?
A virtual molecular tumor board is a digital platform that allows cancer care teams to meet remotely and discuss patient cases. Medicai’s Cloud PACS enables these virtual meetings by providing reliable access to necessary medical imaging and data from anywhere.
Do all cancer cases go to a tumor board?
Typically, only complex or unusual cancer cases, or those where the treatment path is not straightforward, are reviewed by a molecular tumor board, where Medicai’s technology supports the detailed analysis required.
What is the purpose of a tumor board?
The primary purpose of a molecular tumor board is to use a multidisciplinary approach to decide on the best treatment options based on a detailed review of each patient’s unique medical profile, facilitated by Medicai’s Cloud PACS.
What does a molecular tumor board do?
A molecular tumor board evaluates complex cancer cases using detailed genomic and imaging data to tailor personalized treatment plans. This interdisciplinary group of experts uses Medicai's platform to access and review necessary information efficiently.
Seamlessly retrieve, view, store, and share medical imaging data with a robust multi-location, cloud PACS storage, zero-footprint DICOM viewers, AI support, and best-in-class sharing capabilities.
Get the Medicai Mobile App
